Mitchell Carter A, Ramessar Koreen, O'Keefe Barry R
Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD, 21702-1201, USA.
Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD, 21702-1201, USA.
Antiviral Res. 2017 Jun;142:37-54. doi: 10.1016/j.antiviral.2017.03.007. Epub 2017 Mar 18.
Many natural lectins have been reported to have antiviral activity. As some of these have been put forward as potential development candidates for preventing or treating viral infections, we have set out in this review to survey the literature on antiviral lectins. The review groups lectins by structural class and class of source organism we also detail their carbohydrate specificity and their reported antiviral activities. The review concludes with a brief discussion of several of the pertinent hurdles that heterologous proteins must clear to be useful clinical candidates and cites examples where such studies have been reported for antiviral lectins. Though the clearest path currently being followed is the use of antiviral lectins as anti-HIV microbicides via topical mucosal administration, some investigators have also found systemic efficacy against acute infections following subcutaneous administration.
许多天然凝集素已被报道具有抗病毒活性。由于其中一些已被提出作为预防或治疗病毒感染的潜在开发候选物,我们在本综述中着手调查有关抗病毒凝集素的文献。该综述按结构类别和来源生物体类别对凝集素进行分组,我们还详细介绍了它们的碳水化合物特异性及其报道的抗病毒活性。综述最后简要讨论了异源蛋白要成为有用的临床候选物必须克服的几个相关障碍,并列举了已报道针对抗病毒凝集素进行此类研究的实例。尽管目前最明确的途径是通过局部粘膜给药将抗病毒凝集素用作抗艾滋病毒杀微生物剂,但一些研究人员也发现皮下给药后对急性感染有全身疗效。